TXMD News and Press, TherapeuticsMD Inc. From 08/15/22

TherapeuticsMD, Inc. (TXMD) Q2 2022 Earnings Conference Call August 15, 2022 8:30 PM ET Company Participants Lisa Wilson - IR Hugh O'Dowd - CEO Michael Donegan - Interim CFO Mark Glickman - Chief Commercial Officer Conference Call Participants Dou...

The following slide deck was published by TherapeuticsMD, Inc. in conjunction with their 2022 Q2 earnings call. For further details see: TherapeuticsMD, Inc. 2022 Q2 - Results - Earnings Call Presentation

Therapeutics MD press release ( NASDAQ: TXMD ): Q2 GAAP EPS of $12.39. Revenue of $28.6M (+24.3% Y/Y). As of June 30, 2022, the Company’s cash on hand totaled $26.3 million, compared with $65.1 million as of December 31, 2021. For further details see: ...

- Quarterly total net revenue of $28.6 million - - ANNOVERA ® TRx of 9,329, an increase of 28% over Q2 2021 - - Conference call scheduled for 8:30 a.m. ET today - TherapeuticsMD, Inc. (“TXMD” or the “Company”) (NASDAQ: TXMD), an innov...

Therapeutics MD ( NASDAQ: TXMD ) is scheduled to announce Q2 earnings results on Monday, August 15th, before market open. The consensus EPS Estimate is -$3.04 (-2663.6% Y/Y) and the consensus Revenue Estimate is $23.2M (+0.9% Y/Y). Over the last 1 year, TXMD has beat...

-Executive Management to Host Conference Call on August 15, 2022, at 8:30 a.m. ET- TherapeuticsMD, Inc. (“TXMD” or the “Company”) (NASDAQ: TXMD), an innovative, leading women’s healthcare company, today announced that it will report its second ...

TherapeuticsMD ( NASDAQ: TXMD ) received a $15M private investment in its common stock and a new series of preferred stock PIPE from Rubric Capital Management. Proceeds to be used for fulfilling its near-term operating capital requirements. In exchange for its ini...

Company Also Reaches Agreement with Sixth Street Partners to Extend the Maturity Date of its Financing Agreement to September 30, 2022 with the Ability to Extend to November 30, 2022 if Additional Capital is Received TherapeuticsMD, Inc. (NASDAQ: TXMD), (“...

The shares of the women’s healthcare company TherapeuticsMD ( NASDAQ: TXMD ) surged ~12% on Tuesday after one of its leading institutional holders Rubric Capital Management announced the purchase of approximately 82.6K of company shares. The hedge fund which had...

The biotech investment sector has always been its own market, very distinct from other sectors. So it was no surprise that when most sectors turned slowly upward after the pandemic-inspired crash, Biotech (XBI) rose 164%, exceeding the overall market (SPY) performance by triple digits. Then, a...